US Volleyball Players Challenge IOC Genetic Testing

The United States women's volleyball team, with the public backing of USA Volleyball, has voiced serious concerns regarding the International Olympic Committee's (IOC) reintroduced genetic testing policy for the women's category, labeling the process as "invasive" and lacking transparency.

For the first time, a US national sports body is challenging the policy that mandates all female athletes aspiring to compete in Olympic events undergo screening for the SRY gene. The American players, who have already completed these tests via the International Volleyball Federation (FIVB), issued a joint statement expressing their dissatisfaction.

The IOC policy, announced in March, stipulates that athletes testing positive for the SRY gene—typically responsible for the development of male physical characteristics—are ineligible for the women's category, except under rare and specific circumstances. It is precisely the implementation of this rule, particularly the lack of clarity regarding the consequences of a positive result, that is fueling the protest.

The athletes expressed their "concern about the lack of an independent and clearly defined appeals process in the event of disputed or false-positive results." In their statement, they emphasized that "any policy with such serious consequences must include transparent due process protections, confirmation procedures, and athlete advocacy safeguards."

The players, currently competing in the Volleyball Nations League, feel they have been placed in an "impossible position: submit to invasive genetic screening or risk losing the opportunity to compete in the sport and profession to which we have dedicated our lives." They further added that "this dynamic does not appear collaborative, informed, or athlete-centric."

Another major concern revolves around the privacy and security of their medical data. "At the time of testing, athletes were not clearly informed about where this data will be stored, who will have access to it, how it will be protected, how long it will be retained, or what limitations exist on its future use," the statement detailed.

The IOC policy includes an exception for athletes who, despite testing positive, can demonstrate through additional examinations that they have Complete Androgen Insensitivity Syndrome (CAIS) or another rare condition preventing typical development. In an updated FAQ document from May 22, the IOC stresses that such cases are "extremely rare" and that it will be up to the athlete to decide whether to undergo further evaluation.

This stance by the American team follows strong opposition in countries like France and Norway, where the IOC's policy directly conflicts with national laws. French legislation, for instance, prohibits genetic testing outside of very specific medical, judicial, or scientific research contexts. French Sports Minister Marina Ferrari has already highlighted that the government cannot legally conduct or fund these mandatory screenings.

Meanwhile, several organizations, including the Sport and Rights Alliance and Humans of Sport, continue to challenge the scientific and ethical basis of the IOC's guidelines. They argue that the policy will almost exclusively affect athletes with Differences of Sexual Development (DSD), rather than transgender athletes, whose participation in the Olympic Games has been negligible.